Issn Print: 1058-2916
Publication Date: 2000/03/01
DEVELOPMENT OF AN IMPLANTABLE CENTRIFUGAL PUMP FOR RIGHT VENTRICULAR ASSIST: AN ALTERNATIVE STRATEGY FOR THE DEVELOPMENT OF TOTAL ARTIFICIAL HEART
H. Nishida; K Yamazaki; S. Kihara; K. Uwabe; S. Noji; Y. Tomizawa; M. Endo; H. Koyanagi; K. Higuchi; T. Mori
Excerpt
Pulsatile left ventricular assist devices (LVAD) such as Novacor and TCI have been widely used clinically as either a bridge to heart transplantation or definitive treatment for end-stage heart failure. Recently, the clinical usage of non-pulsatile LVADs such as NASA-DeBakey Pump or Jarvik 2000 have also been started. Although biventricular support is necessary in approximately 15% of patients with end-stage heart failure, development of a total artificial heart (TAH) has still a long way to go. To save such patients, the most realistic strategy may be to develop an implantable, non-pulsatile and compact right ventricular assist device (RVAD) that can be used with an implantable pulsatile or non-pulsatile LVAD. Based on the design of a prototype of implantable centrifugal LVAD currently under development (Sun Medical Technology Research Corporation, Suwa, Japan), we have developed RVAD with similar design. Targeted flow performance was 6 L/min against a 50 mmHg afterload at 2000 rpm. The outer diameter of the fin is 36 mm which is 90% of that of LVAD. The calculated mean electric power requirement is 4.5W which is 60% of that of LVAD. The calculated efficiency of the pump is 45%. We believe this RVAD can be implanted into the right upper quadrant of the abdominal wall and be powered from a common battery source with LVAD. Total energy requirement of this RVAD and LVAD, approximately 15W is not more than that of TAH currently under development. In conclusion, combined use of this compact implantable centrifugal RVAD with LVAD can be a promising alternative to the TAH.
Facebook
Twitter
LinkedIn
Email
